The Cancer Imaging Archive (TCIA) Public Access

Space shortcuts

Child pages
  • Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor (AREN0532)

Versions Compared

Old Version 9

changes.mady.by.user Erica Bilello

Saved on

compared with

New Version 10

changes.mady.by.user Geri Blake

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Summary

Excerpt

Summary

Image Added

This collection contains data from the Children’s Oncology Group (COG) Clinical Trial NCT00352534, “Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor," Study Chair: Conrad Fernandez, MD. It was sponsored by NCI and performed by the Children's Oncology Group under study number AREN0532. Brief Summary:
This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.  

                                                                                                                                                                                                                                                                                                                                                                                Image Removed

                                                                                                                                                                     

                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                             

Select patient-level clinical data from this trial is available via the following link: https://nctn-data-archive.nci.nih.gov/node/737.




Localtab Group


Localtab
activetrue
titleData Access

Data Access

This is a limited access data set. To request access please register an account on the NCTN Data Archive.  After logging in, use the "Request Data" link in the left side menu.  Follow the on screen instructions, and enter NCT00379340 when asked which trial you want to request.  In step 2 of the Create Request form, be sure to select “Imaging Data Requested”. Please contact NCINCTNDataArchive@mail.nih.gov for any questions about access requests.

Data TypeDownload all or Query/Filter

Images , Segmentations, and Radiation Therapy Structures/Doses/Plans (DICOM, XX.X GB)

<< latter two items only if DICOM SEG/RTSTRUCT/RTDOSE/PLAN exist >>


Tcia button generator



Tcia button generator
labelSearch



(Download requires the NBIA Data Retriever)

Tissue Slide Images (SVS, XX.X GB

)

Tcia button generator
Tcia button generator
labelSearch
Clinical data (CSVlink)


Tcia button generator
Genomics (web)
Tcia button generator
labelSearch



Click the Versions tab for more info about data releases.

Please contact help@cancerimagingarchive.net  with any questions regarding usage.


Localtab
titleDetailed Description

Detailed Description

Image Statistics


Modalities


Number of Patients

606

Number of Studies

1150

Number of Series


Number of Images


Images Size (GB)

I. Evaluate the overall and event-free survival of younger patients with newly diagnosed stage I favorable histology Wilms' tumor (< 2 years of age and < 550gms) treated with nephrectomy only (very low risk), or with newly diagnosed stage III favorable histology Wilms tumor with possible nephrectomy followed by vincristine, dactinomycin, doxorubicin hydrochloride, and radiotherapy (standard risk).

SECONDARY OBJECTIVES:

I. Determine the effects of adding doxorubicin hydrochloride to the regimen for patients with stage I or II favorable histology found to have a high-risk biological marker.

II. Determine whether the omission of adjuvant therapy increases the incidence of contralateral kidney lesions in patients with very low-risk disease treated by nephrectomy and observation only.

III. Determine whether the omission of adjuvant therapy increases the incidence of renal failure in patients with very low-risk disease who have metachronous relapse.

IV. Correlate study outcomes in patients with standard-risk disease with biological data from tissue collections on protocol study COG-AREN03B2.

OUTLINE: This is a multicenter study. Patients are stratified according to clinical and biological risk factors (very low risk vs standard risk).

STRATUM I: (very low-risk disease) Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.

STRATUM II: (standard-risk, stage I or II disease with adverse biological marker) Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.

STRATUM III: (standard-risk, stage III disease) Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.

After completion of study treatment, patients are followed periodically for up to 8 years.

Include Page
National Clinical Trials Network (NCTN) Date Handling
National Clinical Trials Network (NCTN) Date Handling


Localtab
titleCitations & Data Usage Policy

Citations & Data Usage Policy

This is a limited access data set. Upon receiving access, you must abide by the terms of your NCTN/NCORP Data Archive’s Data Use Agreement (DUA). You are not allowed to redistribute the data or use it for other purposes. Attribution should include references to the following citations:

Info
titleData Citation

Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, Anderson J, Gastier-Foster J, Shamberger RC, Kim Y, Grundy PE, Dome JS; AREN0532 and AREN0533 study committees. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol. 2019 Oct 20;37(30):2769-2777. doi: 10.1200/JCO.18.01972. Epub 2019 Aug 26.Fernandez, C. V., Mullen, E. A., Chi, Y.-Y., Ehrlich, P. F., Perlman, E. J., Kalapurakal, J. A., Khanna, G., Paulino, A. C., Hamilton, T. E., Gow, K. W., Tochner, Z., Hoffer, F. A., Withycombe, J. S., Shamberger, R. C., Kim, Y., Geller, J. I., Anderson, J. R., Grundy, P. E., & Dome, J. S. (2018). (Verify authorship & publication citation)


Info
titlePublication Citation

Fernandez CV, C. V., Mullen EA, E. A., Chi YY, Y.-Y., Ehrlich PF, P. F., Perlman EJ, E. J., Kalapurakal JA, J. A., Khanna, G., Paulino AC, A. C., Hamilton TE, T. E., Gow KW, K. W., Tochner, Z., Hoffer FA, F. A., Withycombe JS, J. S., Shamberger RC, R. C., Kim, Y., Geller JI, J. I., Anderson JR, J. R., Grundy PE, P. E., Dome JS& Dome, J. S. (2018). Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Children’s Oncology Group Study AREN0532. J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6. Erratum in: J Clin Oncol. 2019 Oct 10;37(29):2710.

Info
titleAcknowledgement

lFernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, Anderson JR, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg. 2017 Apr;265(4):835-840. doi: 10.1097/SLA.0000000000001716.In Journal of Clinical Oncology (Vol. 36, Issue 3, pp. 254–261). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2017.73.7999


Info
titleTCIA Citation

Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M., Tarbox, L., & Prior, F.  (2013). The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, . In Journal of Digital Imaging , Volume (Vol. 26, Number Issue 6, December, 2013, pp 1045-1057. DOI: , pp. 1045–1057). Springer Science and Business Media LLC. https://doi.org/10.1007/s10278-013-9622-7

Other Publications Using This Data

TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you'd like to add please contact the TCIA Helpdesk.


Localtab
titleVersions

Version

X

1 (Current): Updated yyyy/mm/dd

Data TypeDownload all or Query/Filter
Images (DICOM, xx.x GB)


Tcia button generator



Tcia button generator
labelSearch



(Requires NBIA Data Retriever.)

Clinical Data (CSV)LinkOther (format)
Tcia button generator
labelSearch
<< One or two sentences about what you changed since last version.  No note required for version 1. >>